RxDoctor Payments Data

Melva Bowman, MD

Family Medicine · Hamlet, NCNPI 1992895361

Payments from drug & device makers

$523in general payments, 2019–2025

Across 34 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$163
  • Boehringer Ingelheim$84
  • Novo Nordisk$67
  • Merck$60
  • Abbott$34
  • Pfizer$32
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$50897%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$523 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$125,483
Medicare patients
196
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$48,281
LinzessLinaclotide45$33,447
JanuviaSitagliptin Phosphate43$32,568
EliquisApixaban40$31,480
OzempicSemaglutide17$27,014
TrulicityDulaglutide20$20,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,332
Tresiba Flextouch U-100Insulin Degludec31$17,032
MounjaroTirzepatide15$15,560
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$13,955
JanumetSitagliptin Phos/Metformin Hcl16$13,232
FarxigaDapagliflozin Propanediol12$12,044
GlyxambiEmpagliflozin/Linagliptin14$8,273
SymbicortBudesonide/Formoterol Fumarate20$7,541
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen305$7,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$84$62,71474 claims
MerckJanuvia, Janumet$60$45,80059 claims
Lilly USA, LLCTrulicity, Mounjaro$163$36,18135 claims
PfizerEliquis$32$31,48040 claims
Novo NordiskOzempic$67$27,01417 claims
GSKTrelegy Ellipta$12$19,33223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hamlet

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →